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Abstract 
Background: The potential benefits of long-acting injectable chemoprotection (LAI-C) against malaria 
have been recently recognized, prompting a call for suitable candidate drugs to help meet this need. On 
the basis of its known pharmacodynamic and pharmacokinetic profiles after oral dosing, ELQ-331, a 
prodrug of the parasite mitochondrial electron transport inhibitor ELQ-300, was selected for study of 
pharmacokinetics and efficacy as LAI-C in mice.  
Methods: Four trials were conducted in which mice were injected with a single intramuscular dose of 
ELQ-331 or other ELQ-300 prodrugs in sesame oil with 1.2% benzyl alcohol; the ELQ-300 content of the 
doses ranged from 2.5 to 30 mg/kg. Initial blood stage challenges with Plasmodium yoelii were used to 
establish the model, but the definitive study measure of efficacy was outcome after sporozoite 
challenge with a luciferase-expressing P.yoelii, assessed by whole-body live animal imaging. Snapshot 
determinations of plasma ELQ-300 concentration ([ELQ-300]) were made after all prodrug injections; 
after the highest dose of ELQ-331 (equivalent to 30 mg/kg ELQ-300), both [ELQ-331] and [ELQ-300] were 
measured at a series of timepoints from 6 hours to 5 ½ months after injection.  
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Results: A single intramuscular injection of ELQ-331 outperformed four other ELQ-300 prodrugs and, at 
a dose equivalent to 30 mg/kg ELQ-300, protected mice against challenge with P. yoelii sporozoites for 
at least 4 ½ months. Pharmacokinetic evaluation revealed rapid and essentially complete conversion of 
ELQ-331 to ELQ-300, a rapidly achieved (< 6 hours) and sustained (4-5 months) effective plasma ELQ-300 
concentration, maximum ELQ-300 concentrations far below the estimated threshold for toxicity, and a 
distinctive ELQ-300 concentration vs. time profile. Pharmacokinetic modeling indicates a high-capacity, 
slow-exchange tissue compartment which serves to accumulate and then slowly redistribute ELQ-300 
into blood, and this property facilitates an extremely long period during which ELQ-300 concentration is 
sustained above a minimum fully-protective threshold (60-80 nM).  
Conclusions: Extrapolation of these results to humans clearly predicts that ELQ-331 should be capable of 
meeting and far-exceeding currently published duration-of-effect goals for antimalarial LAI-C. Allometric 
scaling from mice to humans would predict a several-fold enhancement in the relationship between 
duration-of-effect and dose, and available drug engineering and formulation technologies would be 
expected to offer significant improvement over the simple powder in sesame oil used here. 
Furthermore, the distinctive pharmacokinetic profile of ELQ-300 after treatment with ELQ-331 may 
facilitate durable protection using a variety of delivery and formulation options, and may enable 
protection for far longer than 3 months. Particularly in light of the favorable pharmacodynamic profile of 
ELQ-300, ELQ-331 warrants consideration as a leading prototype for LAI-C.   
Background 
Despite a remarkable recent reduction in the global burden of malaria, there remains an urgent need for 
novel antimalarial drug treatments. It is evident that new drugs are needed to maintain efficacy in the 
face of emerging drug resistance, but even in the absence of drug resistance there are settings and sub-
populations in which drugs are unavailable, unaffordable, impractical, ineffective, or unsafe. These 
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concerns clearly apply to current prevention and treatment applications and are only magnified when 
future eradication efforts are also considered. For some needs, many antimalarial drug options exist, for 
others only a few, and for some none at all. For this reason, thought-leaders in the field have sought to 
identify critical gaps in antimalarial drug options, to define the ideal characteristics of drugs to fill each 
gap, and to disseminate that information in the form of Target Product Profiles (TPPs) (1). 
Until recently, TPPs have focused on maintaining or improving the effectiveness of drugs for 
conventional uses: treatment of malaria, prophylaxis in the non-immune facing new malaria exposure, 
and intermittent prophylaxis in critical sub-groups among populations with endemic exposure. Missing 
from this list has been any role for drugs to achieve sustained, large scale malaria prevention among 
populations in endemic regions. It has been long-hoped that a vaccine could provide the effective and 
durable protection needed for that purpose, and long-assumed that drug treatment could not feasibly 
achieve it. The importance and the urgency of finding options to provide effective and durable 
protection has increased as strategies to eradicate malaria have been considered. Whether by 
protecting the whole population early in the process, or more likely by targeting critical groups late in 
the process, it is evident that sustained, reliable protection against infection and transmission will be an 
absolute requirement for future successful eradication efforts. 
The results of vaccine studies to-date indicate that a feasible, highly-effective, and durably-protective 
vaccine will not be available soon (2). At the same time, an increasing body of information has 
demonstrated the safety and efficacy of long-acting injectable (LAI) medications to treat other 
conditions (3-6), and pilot studies have shown durable protection against malaria in mice after 
intramuscular (IM) drug injection (7, 8). Together, these observations prompted the Medicines for 
Malaria Venture (MMV) to develop the first drug TPP for long-acting injectable chemoprotection (LAI-C) 
against malaria (9). 
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As a starting point, the MMV suggested the following priorities for LAI-C candidates: (1) Multi-stage 
activity including liver and blood stage schizonticidal, and transmission-blocking efficacy, (2) rapid-onset 
high efficacy, sustained for 3 months, (3) minimal or no consequential drug-drug interactions, (4) high 
safety and tolerability both at the injection site and systemically, including in pediatric patients and 
those with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, and (5) formulations with suitable 
viscosity (injectable through small-bore needles), shelf-life (>2-3 years in tropical conditions), and low 
cost. The history of drug resistance development during blood stage infection has led to the 
recommendation that two drugs with the above features be combined for LAI-C, but it is acknowledged 
that a single drug might prove adequate, given the likely diminished risk of de novo drug resistance 
during causal prophylaxis. Because drugs used for LAI-C will be present at the injection site, in blood, 
and in tissues for a very long time period, safety testing will be more complex, lengthy, and costly than 
that for other drug applications. Since any prior toxicology information will therefore be essential to 
down-select appropriate drugs for LAI-C, the MMV has suggested dividing candidates for LAI-C into 
three conceptual groups: tier 1, comprised of existing pharmaceuticals with available clinical safety 
information; tier 2, new drugs which can be delivered orally for initial safety testing; and tier 3, drugs 
that can only be tested parenterally because adequate oral delivery is not possible.  
Very few antimalarials provide causal prophylactic efficacy, so tier 1 candidates include only 
atovaquone, with or without proguanil; the anti-folates, sulfadoxine and pyrimethamine; and the 8-
aminoquinolines, primaquine and tafenoquine. While each has attractive features, each has liabilities. 
Atovaquone has a remarkable propensity to rapidly generate high-grade resistance (10), although that 
risk is likely less during causal prophylaxis and may be further mitigated by the diminished 
transmissibility of highly atovaquone-resistant parasites (11). To match a partner drug and provide 
effective coverage for three months, the relatively short elimination half-life of proguanil (12) would 
mandate a very large delivered dose and attendant possible toxicity risk, or extensive formulation 
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engineering to control release from the injection site. The antifolates face widespread, pre-existing drug 
resistance (13), and although antifolate-caused life-threatening dermatologic toxicity (e.g., Stevens-
Johnson syndrome) is uncommon (14), the risk likely precludes consideration of these drugs for LAI-C. 
Although recent studies indicate the safety and efficacy of some 8-aminoquinoline dosages in some 
patients with G-6-PD deficiency (15), LAI-C would result in months of continuous oxidative stress making 
it almost certain that G-6-PD testing would be required prior to use, and likely that G-6-PD deficiency 
would be a contraindication for 8-aminoquinoline LAI-C. Furthermore, 8-aminoquinolines could be 
ineffective in the small but significant proportion of the population lacking adequate CYP 2D6 to form 
active metabolites (16). From among these tier 1 candidates, atovaquone may be the most promising, 
but no single drug or two-drug combination appears likely to provide sufficiently feasible, effective, and 
safe LAI-C in the context of eradication efforts in regions of high endemicity.   
ELQ-300 (see Table 1) is an experimental antimalarial with causal prophylactic, blood stage 
schizonticidal, and transmission-blocking activity (17). It acts at the Qi site of cytochrome bc1 to 
selectively inhibit parasite mitochondrial electron transport and inter-related pyrimidine biosynthesis 
(17, 18), thus preventing nucleic acid synthesis. ELQ-300 has low nanomolar efficacy in vitro against  
Table 1 title: Structures of ELQ-300, ELQ-331, and other ELQ-300 prodrugs included in this report 
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Table 1 legend : The synthesis, chemical analysis, physicochemical properties, and other details related 
to ELQ-300 and ELQ-331 are previously published (17, 19). ELQ-494, ELQ-495, ELQ-499, and ELQ-500 will 
be described as part of a future report covering the entire scope of the ELQ-300 prodrug project.  
blood stage Plasmodium falciparum, vivax (17), and knowlesi (personal communication, D.A. van  
Schalkwyk) including multidrug-resistant laboratory strains and clinical isolates, and distinctly notable 
transmission-blocking potency (20). Compared to atovaquone, which acts at the Qo site of cytochrome b 
and rapidly gives rise to drug resistance in vitro, the propensity to develop ELQ-300 resistance is far 
lower (>10-5 for atovaquone, <10-8 for ELQ-300) (17, 21). Inhibition of cytochrome bc1 electron transport 
by ELQ-300 is also far more parasite-specific (IC50 P. falciparum = 0.56 nM, IC50 human = >10,000 nM) 
when compared to atovaquone (IC50 P. falciparum = 2 nM, IC50 human = 460 nM) (17). In extensive pre-
clinical testing, ELQ-300 has an excellent safety profile, no evident in vitro drug-drug interactions, and 
slow elimination which facilitates single-dose cures in mice. Oral bioavailability is adequate to prove 
efficacy and to evaluate pharmacokinetics (PK) in animals, but the poor aqueous solubility and high 
crystallinity of ELQ-300 limits the extent and predictability of exposure after oral dosing, making it 
unsuitable as an orally-delivered drug, despite its other favorable features. 
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To improve oral bioavailability while preserving the highly desirable features of ELQ-300, we have 
sought to develop prodrugs of ELQ-300 that are better absorbed from the gastrointestinal tract but then 
are rapidly converted to ELQ-300 (19, 22). ELQ-331 (see Table 1), an alkoxycarbonate ester of ELQ-300, 
has emerged as a leading contender. ELQ-331 also has limited aqueous solubility, but with far less 
tendency to form insoluble crystals and, probably on that basis, results in much-increased ELQ-300 
exposure after oral dosing. In mice, the in vivo efficacy of ELQ-331 by gavage is superior to ELQ-300 (19), 
and in rats, 10 mg/kg of an ELQ-331 formulation resulted in a mean maximum plasma [ELQ-300] of 12.6 
µM (manuscript submitted). ELQ-331 has undergone successful efficacy testing against blood stage 
infection and sporozoite challenge in mice (19), and toxicology assessment rats (see Additional File 1); 
and we continue to advance ELQ-331 and other prodrugs for oral use. It is evident, however, that the 
pharmacodynamic and PK features of ELQ-331 are ideal for a LAI-C candidate, and that physicochemical 
features which are problematic for oral dosing might be beneficial for its use as a LAI-C. We therefore 
undertook the following studies in mice to assess the efficacy and PK profile of IM ELQ-331 in sesame 
oil, and to conduct a limited comparison with other ELQ-300 prodrugs. 
Methods 
ELQ-300 prodrug treatment in mice: All treatments were administered in 0.05 mL of sesame oil 
containing 1.2% benzyl alcohol (v/v), injected through a 0.625-inch, 25 gauge needle into the caudal 
thigh of mice weighing 25-35 gm. To facilitate comparisons, prodrug doses were calculated and are 
expressed on the basis of ELQ-300 content. For example, mice in “10 mg/kg” ELQ-331 treatment groups 
received 12.1 mg/kg of ELQ-331, the molar equivalent of 10 mg/kg of ELQ-300. Stable solubility of each 
prodrug in the injection vehicle was determined prior to dosing (see Additional File 2).  
Blood stage challenges to assess activity against blood stage infection: Blood stage challenges were 
done using a lethal P. yoeliiK parasite (subsp. yoelii, Strain K (Kenya), BEI Resources, NIAID, NIH: MRA-
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428, contributed by Wallace Peters and Brian L. Robinson). Mice were injected intravenously via tail vein 
with 3 X 105 P. yoeliiK-infected erythrocytes and evaluated by microscopy of Giemsa-stained blood 
smears 5 days later. Mice that remained parasite-free were reassessed by blood smears weekly for at 
least 28 days, at which time they were scored as “not infected”. Mice with any evident parasitemia at 
any time point during the study were scored as “infected” and euthanized.  
Sporozoite challenges to assess causal prophylactic activity: Sporozoite challenges were done using a 
transgenic, non-lethal P. yoelii XNL parasite that constitutively expresses a GFP-luciferase fusion protein 
throughout the life cycle (Py-GFP-luc) (23). Female six to eight-week-old Swiss Webster (SW) mice were 
injected with Py-GFP-luc-infected blood to begin the growth cycle. The infected mice were used to feed 
female Anopheles stephensi mosquitoes after gametocyte exflagellation was observed. Ten days after 
the blood meal, 15–20 mosquitoes were dissected to evaluate midgut oocyst formation. At day 14 or 15 
post-blood meal, salivary glands were removed, sporozoites liberated using a pestle and then isolated by 
centrifugation through glass wool. Sporozoites were then counted by hemocytometer and diluted with 
incomplete RPMI to a concentration of 5 X 105 per mL. Samples were maintained on ice from the time of 
salivary gland dissection until final dilution in RPMI. Mice were then injected with 0.2 mL (105 
sporozoites) intravenously via tail vein and evaluated by whole-animal bioluminescence imaging 2 days 
after inoculation to assess liver infection, and 5-6 days after inoculation to determine if blood stage 
infection occurred. 
Whole-animal imaging was done using the IVIS Spectrum CT and Living Image software (Perkin-Elmer). 
Mice were injected intraperitoneally with 150 mg/kg D-luciferin (XenoLight, Perkin-Elmer) in PBS, 10 
minutes prior to imaging, then shortly before and throughout imaging, anesthesia was induced and 
maintained with isoflurane. If no luminescence signal was evident using auto exposure settings, 
exposure time was increased in stepwise fashion to at least 2 minutes at widest aperture. Optimal 
settings often varied between imaging sessions, but for all groups of mice compared head-to-head at 
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any given time point, all camera and software settings were identical. Image assessment was qualitative 
only, to determine the presence or absence of evident infection. 
Blood sampling and processing for determination of plasma ELQ-331 and ELQ-300 concentration: Mice 
were warmed for 5-10 minutes under a lamp prior to sampling. A fifty microliters blood sample was 
collected from a tail vein using a calibrated, heparinized microcapillary tube, and transferred to a 
microfuge tube containing 5.7 µL of 500 mM sodium fluoride, maintained in an ice bath before and after 
sampling. This protocol had been previously shown by us to limit ex vivo esterase metabolism of ELQ-
331 to <2% (see Additional File 2). At each time point, after all required mice were sampled, the 
specimens were moved to a cold room, centrifuged at high speed for 1 minute and then 20 µL of 
supernatant plasma was transferred to a new tube, which was immediately frozen at -80° C until 
analysis.   
Analytical methods for determination of plasma ELQ-331 and ELQ-300 concentration: Prodrug and drug 
concentrations were analyzed using an Applied Biosystems QTRAP 4000 (Foster City, CA) with 
electrospray ionization in positive mode. The mass spectrometer was interfaced to a Shimadzu 
(Columbia, MD) SIL-20AC XR auto-sampler followed by two LC-20AD XR LC pumps. The instrument was 
operated with the following settings: source voltage 5500 kV, GS1 20, GS2 50, CUR 15, TEM 600, and 
CAD MEDIUM.  The scheduled Multiple Reaction Monitoring (MRM) transitions monitored are listed in 
the table below; the bold are used for quantification. Compounds were individually infused and 
instrument parameters optimized for each MRM transition.  A gradient mobile phase was delivered at a 
flow rate of 0.3 mL/min; it consisted of two solvents: A - 0.1% formic acid in water and B - 0.1% formic 
acid in acetonitrile. Separation was achieved using a Dacapo DX-C18 column at 40°C and the 
autosampler was kept at 30°C to prevent the precipitation of ELQ and related compounds. The gradient 
elution was as follows: 40% B, held for 0.5 min; increase to 95% B at 3 min; 100% B was held for 2.5 min; 
decrease to 40% B over 0.1 min; hold at 10% B for 1.4 minutes to re-equilibrate.  Method modification 
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was necessary to separate ELQ-331 from the ELQ-300 as there was in-source fragmentation which 
initially gave erroneous values for ELQ-300 in the presence of ELQ-331. The retention times were 3.09 
minutes for ELQ-300, 2.91 minutes for ELQ-316 (internal standard for ELQ studies [IS]) and 2.98 minutes 
for ELQ-331; separate curves were prepared routinely for ELQ-300 and ELQ-331. Data were acquired 








DP EP CE CXP 
ELQ-300 3.09 476 433.1 166 10 61 12 
ELQ-300 3.09 476 426.1 166 10 61 12 
ELQ-316 
(IS) 
2.91 460 417.1 176 10 59 12 
ELQ-316 
(IS) 
2.91 460 239.1 176 10 83 16 
ELQ-331 2.98 578 476 100 10 45 14 
ELQ-331 2.98 578 433.1 100 10 73 12 
Plasma samples were quickly thawed at room temperature and crashed with freshly prepared 1:9 
dimethylformamide:acetonitrile with 100 ng/mL ELQ-316 internal standard at a ratio of 5 µL plasma to 
95 µL of crash solution.  Samples were vortexed for 2 minutes on a pulsing vortexer, centrifuged for 2 
minutes at high speed, and the supernatant transferred to sample vials.  Prior to analysis the samples 
were pre-heated in the autosampler for a minimum of 45 minutes to ensure stable signal.  A standard 
curve was prepared by spiking commercial mouse plasma with analyte in a range from 1 ng/mL to 2000 
ng/mL, crashed and processed identically to test samples. 
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Pharmacokinetic analysis: Group statistics (mean ± SEM) for plasma drug concentration values and 
graphical representation of concentration vs. time curves were done using Prism 7 software (GraphPad, 
San Diego). The apparent maximum concentration (Cmax) and the time from dosing to Cmax (Tmax) were 
determined by inspection of the results table and graph. When apparent half-life (T1/2) is described for 
any curve segment, it was calculated by the formula: T1/2 = 0.693/kel, where kel = - slope of the 
ln(concentration) vs time curve. Non-compartmental modeling and initial compartmental modeling was 
done using Phoenix WinNonLin 6.4, build 8 (Certara L.P., Princeton, NJ). Since WinNonLin lacks a built-in 
3-compartment model with first-order absorption, final compartmental modeling was performed with 
SimBiology tools in MATLAB software (MathWorks, Natwock, MA). Output PK parameter estimates are 
considered to represent “apparent” rather than physiologic values. 
Summary of all trials: Four separate IM ELQ-331 treatment trials were ultimately performed, the 
rationale for which is described (see Results, below). For reference, Table 2 summarizes the various 
trials to be discussed. Female Swiss-Webster mice (CFW, Charles River Laboratories. Inc. Raleigh, NC) 
were used for Trials 1-3, and female CF-1 mice (Charles River Laboratories. Inc. Raleigh, NC) were used in 
Trial 4. On arrival, the animals were acclimated for at least 7 days in quarantine. The animals were 
housed in a cage maintained in a room with a temperature range of 64−79 °F, 34−68% relative humidity 
and a 12-h light/dark cycle. Food and water were provided ad libitum during quarantine and throughout 
the study. The animals were fed a standard rodent maintenance diet. The study design did not include a 
formal drug toxicity assessment, however, blood sampling afforded frequent opportunities for 
observation of the mice in addition to the standard, ongoing monitoring of animal welfare per protocols. 
Transient or ongoing abnormalities in animal behavior or health, atypical of the normal course of events 
during healthy animal housing, were required to be reported; none were noted.  
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Table 2 title: Summary of the four treatment trials described in this report 
Trial Dose, prodrug 
Time from dosing to testing 




30 mg/kg ELQ-331 
47, 60, 90, 120 days 7, 14, 21, 40 days  137 days 30 mg/kg ELQ-499 
30 mg/kg ELQ-500 
2 30 mg/kg ELQ-331 6, 12, 18, 24, 36, 48, 72 hours; weekly 1-10, 14, 18, 22, 24 weeks n/a 48 days 
3 
10 mg/kg ELQ-331 30, 70, 77 days 
n/a 
77 days 
10 mg/kg ELQ-494 30, 70 days 
n/a 10 mg/kg ELQ-495 30, 70 days 
10 mg/kg ELQ-501 30, 83 days 
4 
2.5 mg/kg ELQ-331 
14, 27 days n/a 
n/a 
5 mg/kg ELQ-331 29 days 10 mg/kg ELQ-331 
 
Results 
Pilot testing for activity against blood stage infection and initial ELQ-300 snapshot PK: In Trial 1 (see 
Figure 1), mice were injected with 30 mg/kg of ELQ-331, ELQ-499, or ELQ-500 on Day 0; controls 
received no drug. To establish initial duration-of-effect parameters to guide subsequent studies, control 
mice and mice from each treatment group were challenged with P. yoeliiK -infected erythrocytes on Day 
7, 14, 21, or 40 after treatment, using a new sub-group of mice (N=3-4) at each timepoint. Blood smears 
of all control mice, at all timepoints, showed patent infection after 5 days (mean parasitemia = 24 ± 
4.9%). All treated mice remained parasite-free for at least 28 days. 
Since these efficacy results indicated the persistence of elevated blood ELQ-300 concentration ([ELQ-
300]), we sought to quantify [ELQ-300] and compare values in the three prodrug treatment groups. Tail 
vein blood samples were obtained 47, 60, 90, and 120 days after treatment (see Figure 1, table insert). 
ELQ-331 produced a more sustained elevation of [ELQ-300] than the other tested prodrugs, remaining 
above 100 nM for 4 months. ELQ-331 was therefore selected for Trial 2, a more detailed PK evaluation 
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(see Pharmacokinetics of 30 mg/kg ELQ-331, below), and the still-persistent elevation of [ELQ-300] 
prompted us to initiate sporozoite challenge testing in the remaining Trial 1 mice (see Causal 
prophylactic efficacy, below).  
Pharmacokinetics of 30 mg/kg IM ELQ-331 in sesame oil: In Trial 2, 24 mice were injected 
intramuscularly with 30 mg/kg ELQ-331 and then divided into 6 groups. Blood samples were obtained 
from one group at each timepoint in a repeating, sequential rotation, so that the same mice were 
sampled at every sixth timepoint. Samples were taken 6, 12, 18, 24, 36, 48, and 72 hours after injection, 
then weekly from 1 to 10 weeks, then every 4 weeks until 22 weeks, and a final sample was taken 24 
weeks after dosing. Plasma [ELQ-331] and [ELQ-300] were measured at each time point (see Figure 2). 
The lower limit of quantitation for [ELQ-331] was 1.2 nM, and values were below that cut-off or non-
detectable in 86% of samples, even in the first days after treatment (see Figure 2, Inset 1). When 
quantifiable, [ELQ-331] levels were trivial (mean = 4 nM, max = 11.5 nM), never reaching 1% of the 
corresponding [ELQ-300]. Importantly, this indicates rapid and highly-efficient metabolism to ELQ-300.  
Variability is evident in [ELQ-300] values at several time points within the first few days (see Figure 2, 
Inset 1). Remembering that each of the first 6 time points represents a different group of mice, we 
speculate that time points with very little variability (e.g., 24 and 36 hours) may represent consistent IM 
delivery to all mice in that group, whereas high variability within a group may indicate that the portion 
of the dose successfully deposited and retained within the muscle varied between mice. If true, then 
early time points with lower and more consistent values may provide a more accurate picture of early 
PK values after IM injection. Some of the highest early [ELQ-300] values may then represent the effect of 
a portion of the dose being deposited or extruded outside the muscle to a site where rapid access to the 
circulation can occur. Given the very small blood volume of a mouse, even a small fraction of the 
injected dose rapidly reaching the circulation could produce transient high µM [ELQ-300], so it is difficult 
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to judge whether or not the early variability actually reflects any substantial variation in the proportion 
of the dose deposited intramuscularly. Our interpretation of [ELQ-300] values determined at later time 
points (see below) is that the early variability here does not indicate substantial loss of the dose from 
the injection site, and that successful dosing was broadly consistent. Since the objective is to rapidly 
reach effective but sub-toxic concentrations, it is notable that at every early timepoint, [ELQ-300] is well 
above 100 nM and does not approach concentrations associated with toxicity established in prior 
studies in rats (see Discussion). With the above caveat in mind, i.e., that several early observed 
timepoints may not be predictive of true IM PK, the ELQ-300 apparent Cmax was 3752 ± 582 nM, at Tmax = 
18 hours.  
The remaining concentration vs. time curve can be divided into 3 apparent phases. Between 
approximately 1 week and 1 month after injection, despite the early variability discussed above, groups 
show remarkably little variability and follow a consistent down-sloping curve with an apparent T1/2 = 14 
days, far longer than the elimination T1/2 seen after intravenous dosing in mice (15 hours) (17). The long 
apparent T1/2 during this phase is a strong indication that absorption of ELQ-300 from the injection site 
into blood is ongoing. More speculatively, the consistency of PK results between and within groups 
during this phase also suggests that, despite the wide variability seen earlier in the same mice, a high 
proportion of the dose was consistently deposited intramuscularly. The next phase of the curve shows a 
decrease in the slope of the concentration vs time curve, which remains relatively flat between 1 and 3 
months after injection. Inserting [ELQ-300] values from Trial 1 reveals remarkable overlap (see Figure 2, 
Inset 2) supporting the validity of the results. After day 90, the downward slope increases for the final 
phase of the curve with an apparent terminal T1/2 = 29.5 days.  
A full discussion of the PK modeling analysis (dataset definition, models comparison, model diagram, 
expressions and equation) is presented in Additional File 3, the results of which will inform future 
analysis and simulations. The main finding relevant to the consideration of ELQ-331 as a prototype for 
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LAI-C is the qualitative finding of a multi-compartment PK profile for ELQ-300, including a large-capacity, 
slow-exchange tissue compartment with significant impact on the duration of ELQ-300 exposure. This is 
demonstrated in Figure 3, showing the curve, parameter estimates, and analysis of fit resulting from 
fitting the “Edited” dataset using a 2-compartment model with first-order absorption and elimination 
(For dataset definition, model diagram, expressions and equation, see Additional File 3). Results confirm 
an excellent fit, with little difference between observed and predicted [ELQ-300] values, and evenly 
distributed residuals. Since the slope of the [ELQ-300] vs. time curve after 30 days cannot be attributed 
to either substantial ongoing absorption of ELQ-300 from the injection site (24, 25) or slow intrinsic 
elimination of ELQ-300 (17), it must be predominantly related to release from the large-capacity 
(Peripheralvol = 4.89 L vs. Centralvol = 0.12 L), slow-exchange (intercompartmental clearance [Q12] = 
0.075 L/h) compartment.  
Causal prophylactic efficacy of ELQ-331 after sporozoite challenge, corresponding plasma [ELQ-300], and 
estimation of MECLAI-C: Mice treated with 30 mg/kg ELQ-331 from Trial 1 (137 days after treatment, N=3) 
and Trial 2 (48 days after treatment, N=4), and untreated controls (N=2) were included in initial Py-GFP-
luc sporozoite challenge testing (see Table 3, upper segment). None of the treated mice developed 
infection; controls had both liver stage and subsequent blood stage infection evident by luminescence 
imaging. The finding that a protective [ELQ-300] was sustained for more than 4 months led us to initiate 
Trial 3, evaluating a lower dose (10 mg/kg) of ELQ-331 in a limited comparison with three additional 
ELQ-300 prodrugs. 
In Trial 3, snapshot PK determinations 30 and 70 days after injection of 10 mg/kg showed that sustained 
[ELQ-300] exposure was greater after ELQ-331 than after injection with long-chain variants ELQ-494 or 
ELQ-495 (see Figure 4, table insert). ELQ-331 thus remained our lead, and sporozoite challenge to these 
mice was done 77 days after injection (see Table 3, middle segment). Whole-body imaging of the mice 
treated with 10 mg/kg ELQ-331, showed no evident liver stage infection, and a faint signal indicating 
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blood stage infection in 1 of 4 animals. Liver stage infection was evident in only 3 of 4 control mice but 
blood stage infection subsequently occurred in all 4, illustrating that the sensitivity of imaging is not 
100%. Although whole-body luminescence imaging is our primary tool and a priori measure to 
determine outcome after sporozoite challenge, we sought to gain added sensitivity by examining blood 
smears of the four ELQ-331-treated mice immediately after imaging. Parasitemia was <0.1% in the 
mouse that was faintly-positive by imaging, <0.01% in 2 mice, and one mouse was parasite-free. On the 
day of imaging, [ELQ-300] values measured in these mice were 92, 75, 66, and 37 nM, suggesting 80 nM 
as an initial estimate of MECLAI-C. 












Liver stage  
(2 days after 
challenge) 
Blood stage 







0/2 (0%) n/a 
ELQ-331, 30 
mg/kg (Trial 1) 137 d   
3/3 (100%) 120 d, 104.9±15.2, 
134, 92, 88 
ELQ-499 137 d 
  
2/3 (67%) 120 d, 72.4±13,  98, 62, 57 
ELQ-500 137 d 
  
    1/4 (25%) 120 d, 65.5±40, 185, 37, 22, 18 
ELQ-331, 30 
mg/kg (Trial 2) 48 d 
  




0/4 (0%) n/a 
ELQ-331, 10 
mg/kg 77 d 
  
3/4 (75%)* 
1/4 (25%) by 
microscopy  
77 d, 67.5±11.4,  
92, 75, 66, 37 
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0/4 (0%) n/a 
ELQ-331, 10 
mg/kg 29 d 
  
4/4 (100%) 
4/4 (100%) by 
microscopy 
27 d,  
95.8±3.7,  
104, 100, 90, 89 
ELQ-331, 5 
mg/kg 29 d 
  
4/4 (100%)* 
2/4 (50%) by 
microscopy 
27 d,  
50.3±5.7,  
61, 58, 46, 36 
* Whole animal imaging was the a priori measure of efficacy, however, blood smear revealed occult 
infection – see text 
Table 3 legend: The upper table segment compares 30 mg/kg prodrug doses; the middle segment, 10 
mg/kg prodrug doses; and the lower segment compares 2.5, 5, and 10 mg/kg ELQ-331 doses. Results 
show more durable protection with ELQ-331 (30 mg/kg, >4 months; 10 mg/kg, >3 months) than other 
tested prodrugs, and MECLAI-C between 60-80 nM (see text) 
To begin to assess the relationship between dose and [ELQ-300] within the first month after ELQ-331 
treatment, and to further explore the MECLAI-C, Trial 4 was initiated to compare 10, 5, and 2.5 mg/kg 
doses of ELQ-331, with 8 mice in each treatment and control group. Snapshot [ELQ-300] determinations 
14 days after dosing in mice from each treatment group (N=4) revealed plasma [ELQ-300] values of 
183±29, 89±10, and 41±7 nM, respectively (see Figure 5, table insert). Measurement of [ELQ-300] was 
repeated 27 days after dosing in the other 4 mice from each group and, excepting the 2.5 mg/kg group 
with earlier sub-effective [ELQ-300], these same mice then underwent sporozoite challenge two days 
later (see Table 3, lower segment). Mice treated with either 5 or 10 mg/kg of ELQ-331 showed no liver 
or blood stage infection evident by imaging 2 or 5 days after inoculation, whereas all controls were 
positive at both timepoints. Blood smears from the mice in the 5 and 10 mg/kg groups were made 7 
days after sporozoite challenge to rule out low-grade infection below the level of detection by imaging. 
No parasites were found among the mice treated with 10 mg/kg or in two of the mice treated with 5 
mg/kg, but smears revealed 1% parasitemia in the other two animals. Weekly blood smears remained 
parasite-free for 28 additional days in the uninfected mice. In the 5 mg/kg treatment group [ELQ-300] 
values were 61, 58, 46, and 36nM, suggesting that in this trial, an estimate of 60 nM might be 
appropriate for the MECLAI-C.  
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This value is substantially lower than the 80 nM value described above, and the source of this difference 
is unclear, but we suspect that it may be the result of differences in the effective inoculum. In the latter 
experiment, there was a much weaker liver stage infection signal in control mice, suggesting that the 
actual delivered inoculum of viable sporozoites was smaller, possibly the result of differences in salivary 
gland transport time and sample processing. The latter experiment also used CF-1 mice, while the mice 
in earlier trials were CFW (CF-1 mice were temporarily unavailable from the supplier), although this 
seems unlikely to account for either reduced infectivity of the Py-GFP-luc sporozoites, or enhanced 
potency of ELQ-300. Since it is unclear how experimental Py-GFP-luc inoculum size relates to predicting 
efficacy against natural infection in humans, it seems prudent to consider 80 nM as a conservative target 
MECLAI-C for LAI-C studies using the Py-GFP-luc sporozoite model in mice.  
We did not design trials to assess MEC separately for causal and suppressive prophylaxis, but we believe 
these MECLAI-C values to reflect true causal prophylaxis, and not suppression of early blood stage 
infection. Per protocol, mice with any evident infection after sporozoite challenge were euthanized, so 
the only opportunity to assess possible suppressive efficacy was in the mice with normal imaging results 
and no parasites on initial blood smear. As noted above, 2 of those mice developed approximately 1% 
parasitemia within 2 days, a rapid growth rate suggesting that [ELQ-300] was well below the effective 
threshold against blood stage infection. Mice with only slightly higher [ELQ-300] were completely 
protected, making it more likely that these values approached the threshold for causal prophylactic 
efficacy instead. This is consistent with study findings after IM atovaquone, in which concentrations that 
protected against sporozoites failed to protect against blood stage challenge (7).  
Discussion 
These results show that a single IM injection of 30 mg/kg ELQ-331 provides more than 4 months of 
causal prophylaxis against malaria in mice and has a distinctive PK profile which contributes to its 
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durable efficacy. These results were achieved using unaltered ELQ-331 dissolved in sesame oil and 1.2% 
benzyl alcohol (as a preservative), without either vehicle optimization or formulation engineering, 
suggesting that further enhancements are likely possible. Translation of these results to predictions of 
efficacy in humans is speculative, but standard allometric scaling (26) provides reason for optimism. If 
the in vivo ELQ-300 MECLAI against species causing malaria in humans is similar to that determined in 
mice, allometric scaling would predict that the duration of effect of a given ELQ-331 dose would be 
several-fold longer in humans than in mice, or, conversely, that a far lower dose would provide the same 
duration of effect. Taken together, these observations suggest a very high likelihood that ELQ-331 can 
feasibly provide the 3 months of protection currently called for in the MMV’s TPP for LAI-C against 
malaria.  
These results are also impressive in comparison to the scant available results from other drugs tested for 
LAI-C. In two studies of engineered drug particles injected IM, mice were protected against P. berghei 
sporozoite challenge for 56 days by a microsuspension of decoquinate (120 mg/kg) in peanut oil (8), and 
for 28 days by atovaquone nanoparticles (200 mg/kg) (7). In unpublished studies of IM prodrugs of 
atovaquone and ELQ-300, apparent MECLAI-c values for atovaquone and ELQ-300 were established based 
on protection against sporozoite challenge 14 days after injection, and duration of efficacy was then 
predicted based on how long the MECLAI-C was exceeded (Presentation by Chatterjee, A.K., TCP4: Intra-
muscular injections for malaria chemoprotection, in Symposium: What kind of molecules are needed to 
control and eradicate malaria? ASTMH 66th Annual Meeting. 2017: Baltimore, MD). No later sporozoite 
challenges were reported, but after 30 mg/kg injections, MECLAI-C was exceeded for more than 13 weeks 
in dogs after the ELQ-300 prodrug (mCBK069), and in rats after the ATV prodrug (mCBK068). Given 
allometric scaling predictions (clearance in mice < rats << dogs), the ELQ-331 performance 
demonstrated here appears to surpass that of other agents for which reports are available. 
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Although sesame oil is used as a vehicle for other LAI drugs, such as haloperidol (5), it is unlikely to 
match the initial specifications set out by the MMV. The TPP for antimalarial LAI-C calls for a small 
volume injection, ideally 1 mL or less in adults (< 2 mL is acceptable) and 0.5 mL or less in infants, and 
that it be injectable through a 27-gauge needle (9). We find ELQ-331 in refined sesame oil to be soluble 
to 83 mg/mL (see Additional File 2). Given that 30 mg/kg of ELQ-331 yields 4-5 months of protection in 
mice, and allometric scaling would suggest 2.5 mg/kg as an equivalent dose in humans, it may or may 
not prove difficult to deliver the dose needed for 3 months of protection for a large adult in 1 mL. Due to 
viscosity, delivery through a very fine needle is problematic for any conventional oil. Oily vehicles 
enhance the solubility of lipophilic drugs such as ELQ-331 and serve to slow release from the injection 
site, and it is unclear how difficult it will be to achieve success with a low viscosity vehicle. ELQ-331 is 
soluble in some low viscosity vehicles, such as Miglyol 840 (see Additonal File 2), and the results of 
solubility testing in several vehicles provide a starting point for optimization. This suggests that 
adequate solubility will be achievable, but it will also be necessary for the vehicle to have a desirable 
drug release profile, local and systemic tolerability, and to be approved for injection use. Viscosity, 
surface area, and composition of the vehicle all impact the time course of drug release from the 
injection site (24), so substantial testing may be needed to find the ideal formulation.  
Given the many advances in dosing formulation technology, there is little doubt that an ideal vehicle is 
possible, but for large-scale use in malaria-endemic regions it will be essential to keep costs low and 
avoid complex vehicle formulations, if possible. If finding an ideal, cost-effective vehicle formulation 
proves difficult, then it is worth discussing whether inexpensive oil vehicles, such as sesame oil, deserve 
consideration for LAI-C dosing. Certainly, use of the smallest bore needles will not be possible with oils, 
but that is a lesser concern. Although the least possible injection discomfort is always desirable, 
immunizations are routinely injected in infants via 23-25 g needles, so if it were ultimately not possible 
to use a 27 g needle that would likely still be acceptable. Another concern expressed with regard to 
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sesame oil is allergy risk, but it is uncertain whether such a risk actually exists. There are clearly cases of 
eosinophilic pneumonitis after repeated daily injections of sesame oil (27), but this results from delayed 
hypersensitivity to significant amounts of absorbed oil and not immediate hypersensitivity-mediated 
acute allergic reaction. The antigens in sesame oil capable of causing dangerous acute allergic reactions 
are present in crude sesame oil, but not in oil refined for pharmaceutical use and most injectable 
pharmaceutical products in sesame oil do not include allergy risk as a contraindication or potential 
adverse effect in product information (28). We were unable to find any documented cases in the 
literature of dangerous acute allergic reaction to pharmaceutical sesame oil, and would argue that it 
should not be ruled out on the basis of allergy risk. Beyond conventional IM injection, LAI-C is also an 
excellent candidate application for other delivery systems such as subcutaneous implant (29) and in situ 
gelling (30) technologies, providing numerous additional options for solubilization and delivery.  
To account for the sustained efficacy of ELQ-331, it is useful to first consider its resulting overall [ELQ-
300] PK profile. During the initial downslope phase (days 7-35), absorption from the injection site, 
distribution to and from tissue compartments, and elimination are likely occurring. ELQ-300 is highly 
metabolically stable, so it is presumed that simple first order processes lead to elimination in feces and 
urine, driven by mass action, and as a result, ELQ-300 elimination should follow a consistent, 
concentration-dependent curve. Therefore, the inflection to a decreased slope of the curve (days 45-90) 
must result from some combination of continued drug absorption, decreased distribution from blood to 
tissue, and increased reabsorption from tissue to blood. While some drug absorption could still be 
occurring at that time, for it to be the predominant cause of this plateau phase would require that fairly 
constant and substantial absorption be ongoing for 3 months or more; this is inconsistent with studies of 
the persistence of oil and drug at intramuscular injection sites in mice (25). Consistent with our 
compartmental PK modeling, it is more likely that redistribution from other tissue compartments to 
blood is predominant over the flat portion of the curve, and that the subsequent increased curve slope, 
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evident after 90 days, results as redistribution from tissue decreases and elimination becomes gradually 
more predominant. This final apparent change in slope is not accounted for in our standard 
compartmental modeling equations, and it will be interesting to see in future studies if it is a 
reproducible PK feature or merely an artifact due to our sampling protocol. 
A full, accurate, and predictive model of IM ELQ-331 pharmacokinetics will be complex since it must 
include the rate of release of ELQ-331 from the injected oil depot; conversion to ELQ-300 by esterases at 
the injection site, in lymph, blood, and in liver and other organs; absorption into blood; extensive 
protein binding in blood; distribution from blood to tissue; redistribution from tissue to blood; and 
elimination, with each component involving its own set of numerous variables (24, 31). As a result, the 
absolute values of parameters estimated from our simple compartmental PK analyses are unlikely to 
represent physiologic values in vivo, but the findings are powerful, nonetheless. Fundamentally 
important is the demonstration that prolonged redistribution of ELQ-300 from tissue sites is critical to 
the sustained elevation of [ELQ-300] seen here. While the slow release of highly-lipophilic ELQ-331 from 
oil and the long-elimination T1/2 of ELQ-300 certainly contribute to a long duration of effect, these are 
properties shared by other antimalarials, whereas the capacity of a large, slow-exchange tissue 
compartment to impact blood drug concentration and efficacy months after dosing is highly unusual, 
and distinguishes ELQ-300 prodrugs such as ELQ-331 from other candidates reported thus far. 
If the ideal PK profile for LAI-C is to rapidly achieve and maintain effective but non-toxic concentrations 
of the active drug, in most cases this would be achieved by balancing elimination with sustained and 
controlled release from the injection site throughout the period of risk. For medications delivered by 
LAI, drug concentrations are typically most dependent on controlled and sustained release from the site 
of delivery, optimized by choice of vehicle, vehicle mixtures, benzyl alcohol or other excipient content, 
drug particle engineering, or other injection parameters (24, 29). This is evident in unpublished data 
regarding atovaquone prodrugs (32), in which day 30 [atovaquone] values are highly dependent on 
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formulation. In contrast, our results suggest that maintaining sustained and effective ELQ-300 
concentrations after IM ELQ-331 is most closely related to loading and gradual unloading of ELQ-300, to 
and from a repository tissue depot. While the pattern of ELQ-331 release from the injection site is 
undoubtedly important in this process, controlled release apparently does not need to be sustained to 
sustain durable protection because of the effect of the secondary depot. Because this PK profile is a 
distinguishing feature of ELQ-331, it is important to consider its possible disadvantages and advantages 
in the setting of LAI-C.   
It will be important to identify the tissues and organs comprising this large-capacity, slow exchange 
compartment to understand its impact on dosing considerations. If distribution is highly concentrated in 
specific organs (e.g., liver), between-subject variability on the basis body mass index (BMI) obesity 
would be less likely, whereas variations in BMI might lead to unwanted variations in response if 
distribution is predominantly to general adipose tissue. Further study will allow development of the 
physiology-based PK models needed to address these questions.  
Extensive and sustained tissue stores of ELQ-300 could, theoretically, also prevent rapid termination of 
exposure in case of toxicity, particularly if the site of toxicity were an organ in which the drug is highly 
concentrated. After typical IM injection, this risk would be similar for any drug, but since removable drug 
delivery systems (e.g., implants, removable gels) are a consideration for LAI-C as a safeguard against 
toxicity, in that context a rich deposit of tissue-bound drug would be a comparative disadvantage. At this 
time, there are no known safety concerns with ELQ-331, but with large required drug payloads, 
sustained drug exposure, and planned use in remote settings with little safety surveillance capacity, the 
safety of any drug used for LAI-C must be viewed skeptically.  
During oral toxicity testing of ELQ-331, rats received a single dose of 15, 30, 100, 300, or 1000 mg/kg, or 
7 daily doses of 5, 50, or 300 mg/kg (see Additional File 1). The lowest single dose with any evident 
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toxicity was 300 mg/kg, which resulted in an ELQ-300 Cmax = 65-79 µM, and after lower doses, 
concentrations well above 27-44 µM caused no apparent adverse effect. Seven daily doses of 5 mg/kg 
(35 mg/kg cumulative) were tolerated without evidence of toxicity; [ELQ-300] values after the last dose 
showed Cmax = 13-17 µM , and indicated that supra-µM concentrations had been maintained throughout 
the week. While neither single nor 7 day dosing mirrors exposure after LAI-C, the very high [ELQ-300] 
values associated with toxicity and the absence of toxicity after either a single 100 mg/kg or cumulative 
35 mg/kg over 7 days are reassuring that the 4-month duration of protection reported here was 
achieved safely (Cmax = < 5 µM).   
If safety is ultimately established, then the ELQ-331 PK profile could be highly advantageous. By 
exploiting intrinsic PK properties to maintain effective ELQ-300 concentrations, a shorter period of 
tightly-controlled release might be needed, lessening the requirement for extensive formulation 
engineering. In fact, if “loading” this compartment is sufficient to sustain concentrations, then this might 
be achievable by many drug delivery routes, including short-term repeated oral dosing. Essentially, this 
property adds another basis for extended efficacy, regardless of dosing strategy, and suggests that 
duration of effect for far longer than 3 months may be more easily achievable with ELQ-300 prodrugs 
than with atovaquone derivatives or other candidates.  
This is advantageous beyond simply meeting the initial 3-month duration-of-effect target. To avoid 
conditions favorable to generation of drug resistance during proposed combination therapy, it is 
important that partner drugs are matched such that neither component falls below the MECLAI during 
the period of risk. Achieving such a match is challenging, particularly if both components require 
significant engineering to meet duration-of-effect requirements. If ELQ-331 requires little or no 
engineering to achieve adequate extended activity, then adjusting duration of effect to match any 
partner drug should be simplified, perhaps only requiring dose adjustment. Alternatively, in settings 
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with a defined finite period of exposure risk, ELQ-331 might facilitate an acceptable PK mismatch in 
which the effectiveness of a partner drug extends to the end of the risk period, but ELQ-331 effect 
continues beyond that time. Finally, more reliable sustained efficacy may support consideration of ELQ-
331 for use without a partner. 
Avoidance of monotherapy is based on the concern that a large number of parasites in the presence of 
sub-effective drug concentrations promotes the generation or selection of resistant parasites. Clearly a 
risk during blood stage infection, the same risk is theoretically possible during late liver stage infection 
when infected hepatocytes house many thousands of developing merozoites. In contrast, an effective 
causal prophylactic that prevents liver schizont development and survival faces less than a hundred non-
replicating parasites, making the risk of resistance generation exceedingly low if not zero. In the absence 
of pre-existing resistance, monotherapy LAI-C is thus a logical consideration if an effective drug 
concentration can safely and reliably be maintained beyond the end of exposure risk. This argument 
applies only to true causal prophylaxis, so it is important to distinguish whether efficacy is solely on that 
basis, or whether results are confounded by suppression of blood stage growth. ELQ-300 retains in vitro 
potency against P. falciparum clinical isolates resistant to quinolines, anti-folates, artemisinin, and 
atovaquone, among others, with no evidence of existing resistance. Generation of ELQ-300 resistance in 
vitro is several orders of magnitude more difficult than with atovaquone, and like the case of 
atovaquone, there is evidence of diminished transmissibility of ELQ-300 resistant parasites (personal 
communication, G. McFadden). Given its multistage efficacy, potency, PK profile, and activity against 
multidrug resistant parasites, ELQ-331 seems an ideal candidate for consideration of study as single-
drug LAI-C, in addition to its less controversial proposed role in 2-component LAI-C.  
To meet shelf-life requirements for LAI-C, ELQ-331 would need to undergo full stability testing in 
whichever formulation is ultimately selected for LAI-C, but existing results are encouraging. Testing for 3 
months at 40° C and 75% humidity showed ELQ-331 in a spray-dried dispersion formulation to be stable 
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(manuscript submitted), and while no long-term testing has been done, it is stable in the short-term 
after heating in sesame oil. Regarding the affordability of ELQ-331 as a component of LAI-C, there are no 
obstacles to scalable, feasible, and cost-acceptable ELQ-331 synthesis, and only the need for an 
unexpectedly complex and expensive final formulation could raise costs to a concerning level.  
The above findings suggest that ELQ-331 is an excellent candidate for use in LAI-C against malaria and, 
that among current tier 2 candidates, its characteristics are distinctly and perhaps uniquely suited to 
that purpose, making it an appropriate prototype for study and comparison. Further studies are 
warranted, including expanded toxicology studies of ELQ-331 relevant to LAI-C, consideration of 
appropriate partner drugs, study of factors relevant to the consideration of monotherapy, exploration of 
other vehicle formulations for IM injection, study of other delivery systems (e.g., implant, in situ gelling 
polymer, oral), and continued comparison with other prodrugs.  
Summary  
A single IM injection of ELQ-331 in sesame oil in mice provided causal malaria prophylaxis for more than 
4 months. Given allometric scaling predictions and available engineering and formulation technologies, 
these results clearly support the feasibility of ELQ-331 to achieve duration of protection against malaria 
for at least 3 months in humans. Furthermore, the distinct PK profile of ELQ-300 after ELQ-331 
treatment may facilitate flexible delivery and formulation options and may also enable protection for far 
longer than 3 months. Particularly in light of the favorable pharmacodynamic profile of ELQ-300, ELQ-
331 warrants consideration as a leading tier 2 prototype for LAI-C. 
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[ELQ-300], [ELQ-331]: Concentration of ELQ-300, concentration of ELQ-331 
G-6-PD: Glucose-6-phosphate dehydrogenase 
IS: Internal standard 
IM: Intramuscular 
LAI-C: Long-acting injectable chemoprotection 
MEC: Minimum effective concentration 
MECLAI-C: Minimum effective concentration for chemoprotection after long-acting injection 
MMV: Medicines for Malaria Venture 
MRM: Multiple reaction monitoring 
PK: Pharmacokinetic 
TPP: Target product profile 
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Figure titles and legends 
Figure 1 title: Summary of Trial 1 protocol and results 
Figure 1 legend: The timepoints for blood stage challenges, blood sampling for snapshot 
pharmacokinetic analysis, and sporozoite challenges are noted on the x-axis. The outcomes of efficacy 
trials are represented graphically as red = no protection and green = complete protection, and the 
proportion of challenged mice with each outcome is noted. The table insert summarizes the results of 
snapshot PK at the indicated timepoints. 
Figure 2 title: Pharmacokinetics of ELQ-300 after IM injection of 30 mg/kg ELQ-331 in Trial 2 
Figure 2 legend: Main figure summarizes Trial 2 PK results in a log-linear plot of [ELQ-300] (mean ± SEM) 
vs time. Inset 1 shows detail of days 0-7 in an expanded linear-linear plot of [ELQ-331] and [ELQ-300] vs 
time. Inset 2 shows a composite log-linear plot combining values from Trial 1 and Trial 2. 
Figure 3 title: Results of 2-compartment model fit 
Figure 3 legend: (A) Linear-linear plot of observed mean [ELQ-300] values at each timepoint (+ symbols) 
and values predicted from the curve fit (line). Estimated model parameters are shown in the insert 
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table. Central = Apparent volume of the central compartment (L); Cl_Central = central compartment 
clearance (L/hr); ka_Central = rate constant for absorption; Peripheral = apparent volume of the tissue 
compartment; Q12 = intercompartmental clearance (L/hr). (B) Indicators of model fit validity: 
correspondence of observed and predicted values, unbiased distribution of residuals. 
Figure 4 title: Snapshot pharmacokinetics of ELQ-300 during Trial 3 
Figure 4 legend: Snapshot plasma [ELQ-300] values from Trial 3, comparing IM injections of 10 mg/kg 
ELQ-331 with two other ELQ-300 prodrugs. The log-linear graphical representation of [ELQ-300] vs. time 
and summary table both display mean [ELQ-300] ± SEM. 
Figure 5 title: Snapshot pharmacokinetics of ELQ-300 during Trial 4 
Figure 5 legend: Snapshot plasma [ELQ-300] values from Trial 4, comparing IM injections of 2.5, 5, and 
10 mg/kg ELQ-331. The log-linear graphical representation of [ELQ-300] vs. time and summary table 
both display mean [ELQ-300] ± SEM. 
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Plasma [ELQ-300] ± SEM, nM
47 205.2 ± 23.8 157 ± 16.9 227.2 ± 40.7
60 225.5 ± 26.7 148.3 ± 43.9 148.3 ± 22.9
90 117.3 ± 30.7 73.1 ± 11.2 88.9 ± 25.9
120 104.9 ± 14.2 72.4 ± 13 65.5 ± 40
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Figure 2  
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Figure 3  
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Figure 4   

















Day 30 Day 70 Day 77
ELQ-331, 10 mg/kg 290.4 ± 16.4 70.5 ± 8.1 67.5 ± 11.4
ELQ-494, 10 mg/kg 67.5 ± 12.8 21.7 ± 5 n/a
ELQ-495, 10 mg/kg 105.9 ± 18.1 37.7 ± 5.2 n/a
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Figure 5 















ELQ-331 dose Plasma [ELQ-300], nMDay 14 Day 27
2.5 mg/kg 40.5 ± 7.3 25 ± 4.9
5 mg/kg 88.6 ± 9.7 50.3 ± 5.7
10 mg/kg 182.7 ± 28.6 95.8 ± 3.7
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